


# ANMC Protocol for 2017-18 Seasonal Flu Vaccine Administration to Children and Adults



## 2017-18 Approved Use of Seasonal Influenza Vaccines

<b>People Recommended To Receive Vaccine</b>	<b>All persons 6 months and older. See criteria below for children &lt;9 years who may require two doses. When vaccine is in short supply, focus on:</b> Children 6 months through 59 months; elders 50 years of age and older; pregnant (or will be pregnant) women; persons with chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, hematologic, neurological, neuromuscular or metabolic disorders (including diabetes); immunosuppression; children 6 months-18 years receiving long-term aspirin therapy; AI/AN; persons morbidly obese (BMI >40), and residents of nursing homes and chronic-care facilities.
--	---

### Inactivated Influenza Vaccine (IIV)

<b>Injectable Vaccine</b> Indication & dosage by product	<p><b>6-35 months – dosage 0.25 mL route IM</b></p> <ul style="list-style-type: none"> <li>Fluzone® Sanofi –Quadrivalent (pf) – 0.25 ml single-dose prefilled syringe preservative-free (pf)</li> <li>Fluzone® Sanofi –Quadrivalent – 0.25 ml drawn from multi-dose 5 mL vial</li> </ul> <p><b>36 months and older – dosage 0.5 mL IM</b></p> <ul style="list-style-type: none"> <li>Fluarix® GSK –Quadrivalent (pf) – 0.5 ml single-dose prefilled syringe preservative-free (pf)</li> <li>Fluzone® Sanofi –Quadrivalent – 0.5 ml drawn from multi-dose 5 mL vial</li> </ul> <p><b>5 years and older – dosage 0.5 mL IM</b></p> <ul style="list-style-type: none"> <li>Afluria® Seqirus –Quadrivalent – 0.5 ml drawn from multi-dose 5 mL vial</li> </ul> <p><b>Adults 18 years and older – dosage 0.5 mL IM</b></p> <ul style="list-style-type: none"> <li>FluBlok® Protein Sciences –Quadrivalent – 0.5 ml prefilled syringe –<b>pharmacy will have a small supply</b> <b>IMPORTANT:</b> FluBlok (RIV4) is an egg-free flu vaccine option for person with severe allergy to eggs</li> </ul> <p><b>Alternative for Adults 65 years and older – dosage 0.5 mL IM</b></p> <ul style="list-style-type: none"> <li>Fluzone High Dose® Sanofi – Trivalent – 0.5 ml prefilled syringe for adults 65 years and older</li> </ul>
---	--

<b>For All Flu Vaccine</b> Contraindication & precautions	<p><b>Contraindications for all influenza vaccines</b></p> <ul style="list-style-type: none"> <li>Severe allergic reaction to the vaccine or to component other than egg. For list of vaccine components in the CDC Pink Book Appendix B, go to: <a href="http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf">http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf</a></li> </ul> <p><b>Precautions for all influenza vaccines</b></p> <ul style="list-style-type: none"> <li>Moderate or severe illness (A person with a mild cold or other mild illness, with or without fever, may be vaccinated).</li> <li>Guillain Barre syndrome within 6 weeks of a previous influenza vaccination.</li> <li>Egg allergy*</li> </ul> <p>*<b>Egg Allergy:</b> CMA/LPN/RN, defer to medical provider. For patients with egg allergy, provider should review the current CDC influenza vaccination recommendations outlined below or available at: <a href="https://www.cdc.gov/mmwr/volumes/66/rr/rr6602a1.htm">https://www.cdc.gov/mmwr/volumes/66/rr/rr6602a1.htm</a></p>
--	--

### PATIENTS WITH EGG ALLERGY

Persons with a history of egg allergy who have experienced only urticaria (hives) after exposure to egg should receive influenza vaccine. Any licensed and recommended influenza vaccine (i.e., any age-appropriate injectable flu vaccine or FluBlok®) that is otherwise appropriate for the recipient's age and health status may be used.

Persons who report having had reactions to egg involving symptoms other than urticaria (hives), such as angioedema, respiratory distress, lightheadedness, or recurrent emesis; or who required epinephrine or another emergency medical intervention, may similarly receive any licensed and recommended influenza vaccine (i.e., any age appropriate injectable flu vaccine or FluBlok®) that is otherwise appropriate for the recipient's age and health status. The selected vaccine should be administered in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, health departments, and physician offices). Vaccine administration should be supervised by a health care provider who is able to recognize and manage severe allergic conditions.

A previous severe allergic reaction to influenza vaccine, regardless of the component suspected of being responsible for the reaction, is a contraindication to future receipt of the vaccine.

### NEED TWO DOSES? Influenza vaccine for children 6 months through 8 years, 2017-18

**Children less than 9 years of age need 1 dose of flu vaccine this season if they have received:**

- At least two total doses of trivalent or quadrivalent influenza vaccine before July 1, 2017. The two doses need not have been received during the same season or consecutive seasons. Doses should be at least 4 weeks apart.

**Otherwise, the child needs 2 doses, with the second dose given a minimum of 4 weeks after the first dose.**

#### Implementation of Protocols

**Outpatient Clinics:** This protocol, signed by the Medical Director, serves as a pre-authorized order for RNs, LPNs, and CMAs who have demonstrated competency to administer vaccines according to the protocol criteria. The immunization event is co-signed in Cerner by the attending provider.

**Inpatient/ER/UCC Department:** Provider orders vaccine in Cerner and RN documents immunization in Cerner MAR. The pneumococcal and influenza immunization screen in the Cerner Patient Admission powerform functions as a nurse-driven protocol used by the RN; an order is generated in Cerner if the patient qualifies for pneumococcal or flu vaccine and the vaccine(s) appear on the MAR. A provider's order is required for all other vaccines, such as Tdap.

<p><b>The Criteria Contained in this Protocol is Derived from:</b> CDC Summary Recommendations: Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP); <a href="https://www.cdc.gov/mmwr/volumes/66/rr/rr6602a1.htm">https://www.cdc.gov/mmwr/volumes/66/rr/rr6602a1.htm</a></p>	<b>PCC Medical Director:</b> <u>M.A. Shyn <sup>for Dr. Corbett</sup></u>	<b>Date:</b> <u>9-21-17</u>
	<b>PCC Nursing Director:</b> <u>Synda Cook</u>	<b>Date:</b> <u>9/21/17</u>
	<b>President Medical Staff:</b> <u>[Signature]</u>	<b>Date:</b> <u>9/28/17</u>
	<b>Chief Nursing Officer:</b> <u>Genevieve Sheppan</u>	<b>Date:</b> <u>9/25/17</u>
	<b>Director of Pharmacy:</b> <u>Kara A. Kilg</u>	<b>Date:</b> <u>9/19/17</u>
<b>These protocols shall remain in effect until June 30, 2018</b>		